ClinicalTrials.gg
CompletedNCT05852691Updated Nov 2, 2026

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

A Phase 2 interventional study of Tobemstomig and Pembrolizumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 36 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

How we know · 8 judgments

Updated Nov 2, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 229 studies in Breast Neoplasms by Hoffmann-La Roche — 16 open to participants now, 27 under way, 13 of them phase 3. Breast Neoplasms · Hoffmann-La Roche.

Enrollment
113th of 170
83 · median 151
Started
2023
with 4 others
Phase 2
65 of 229
4 open now
Registered
211th of 229
by date

Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 113th largest by enrollment of the 170 interventional ones that give a count, is one of 5 that started in 2023, is one of 65 in phase 2, and was the 211th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 229 studies in Breast Neoplasms by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 229 studies in Breast Neoplasms by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or locally advanced unresectable, documented triple-negative breast cancer (TNBC) (absence of -over-expression, ER, and PgR expression by local assessment)
  • HER2-low-status
  • per (RECIST) v1.1
  • If metastatic disease (Stage IV), measurable disease outside of the bone
  • No prior systemic therapy for metastatic or locally advanced unresectable TNBC
  • Tumor expression as documented through central testing of a representative tumor tissue specimen
  • (ECOG) Performance Status of 0 or 1
  • Adequate hematologic and end-organ function
  • Negative test at screening, with the following exception: individuals with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a ≥ 200/uL, and have an undetectable viral load
  • Negative surface antigen (HBsAg) test at screening
  • Positive hepatitis B surface antibody (HBsAb) test at screening, or a negative HBsAb at screening accompanied by either of the following: negative hepatitis B core antibody (HBcAb); positive HBcAb test followed by quantitative hepatitis B virus (HBV) DNA \< 500 IU/mL
  • Negative virus (HCV) antibody test at screening, or a positive HCV antibody test followed by a negative HCV RNA test at screening
  • Adequate cardiovascular function

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 4 months after the final dose of tobemstomig or pembrolizumab, and 6 months after the final dose of nab-paclitaxel
  • Poor venous access
  • History of within 5 years prior to consent, except for the cancer under investigation in this study and malignancies with a negligible risk of or death (e.g., 5-year OS rate >90%), such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  • History of
  • Pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
  • Hypercalcemia or hypercalcemia that is symptomatic
  • Active or history of disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis (granulomatosis with polyangiitis), Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted
  • Active tuberculosis (TB)
  • Significant cardiovascular/cerebrovascular disease within 3 months prior to consent
  • History or presence of an abnormal that is deemed
  • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long syndrome
  • Major surgical procedure within 4 weeks prior to initiation of study treatment
  • Treatment with therapeutic oral or IV antimicrobials (anti-bacterial, anti-fungal, antiviral, anti-parasitic) within 1 week prior to initiation of study treatment
  • Prior allogeneic stem cell or solid organ transplantation
  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an drug, may affect the interpretation of the results, or may render the participant at high risk from treatment complications
  • Treatment with a live, attenuated vaccine within 28 days prior to initiation of study treatment
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Prior treatment with CD137 agonists or anti-CTLA therapeutic antibodies or an anti-LAG3 agent
  • Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and IL-2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment
  • Treatment with systemic or other systemic medications (including, but not limited to, prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF agents) within 2 weeks prior to initiation of study treatment
  • History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
  • Known to Chinese hamster ovary cell products or to any component of the tobemstomig or pembrolizumab formulation
  • Known allergy or hypersensitivity to any component of the to nab-paclitaxel formulation
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Arm A

    Participants will receive tobemstomig every 3 weeks, plus nab-paclitaxel administered on a repeating schedule of 3 weeks on, 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.

    Drug: Tobemstomig · Drug: Nab-Paclitaxel

  • Active comparator
    Arm B

    Participants will receive pembrolizumab every 3 weeks, plus nab-paclitaxel administered on a repeating schedule of 3 weeks on, 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.

    Drug: Pembrolizumab · Drug: Nab-Paclitaxel

Interventions

  • Participants will receive intravenous (IV) tobemstomig every 3 weeks (Q3W) until disease progression or until up to 24 months after the first treatment, whichever is sooner.

    Also known as: RO7247669

  • Participants will receive IV pembrolizumab Q3W until disease progression or until up to 24 months after the first treatment, whichever is sooner.

  • DrugAlbumin-Bound PaclitaxelStudies of Albumin-Bound PaclitaxelAlbumin-Bound Paclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 24 months)

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: Two consecutive occasions at least 4 weeks apart (up to approximately 24 months)

  2. Duration of Response (DOR)

    Time frame: From the first occurrence of a confirmed objective response to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 24 months)

  3. Overall Survival (OS)

    Time frame: From randomization to death from any cause (up to approximately 24 months)

07

Study locations

36 sites
  • Cancer Blood and Specialty Clinic
    Los Alamitos, California 90720, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Novant Health Presbyterain Medical Center
    Charlotte, North Carolina 28204, United States
  • Avera Cancer Institute
    Sioux Falls, South Dakota 57105, United States
  • Centro de Investigaciones Médicas y Desarrollo LC S.R.L
    Buenos Aires, C1113AAE, Argentina
  • Sunshine Hospital
    St Albans, Victoria, Australia
  • Hospital Araujo Jorge
    Goiânia, Goiás 74605-070, Brazil
  • Hospital do Cancer de Pernambuco - HCP
    Recife, Pernambuco 50040-000, Brazil
  • Hospital de Cancer de Barretos
    Barretos, São Paulo 14784-400, Brazil
  • Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
    São Paulo, São Paulo 01317-001, Brazil
  • Fakultni Thomayerova nemocnice
    Praha 4 - Krc, 140 59, Czechia
  • Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH
    Essen, 45136, Germany
  • Dres. Andreas Köhler und Roswitha Fuchs
    Langen, 63225, Germany
  • Universitätsklinikum Ulm Am Michelsberg
    Ulm, 89075, Germany
  • Komarom-Eszergom Varmegyei Szent Borbala Korhaz
    Tatabánya, 2800, Hungary
  • Hadassah University Hospital - Ein Kerem
    Jerusaelm, 9112001, Israel
  • Sheba Medical Center
    Ramat Gan, 5262100, Israel
  • Ospedale Provinciale Santa Maria Delle Croci
    Ravenna, Emilia-Romagna 48100, Italy
  • Ospedale San Raffaele
    Milan, Lombardy 20132, Italy
  • Health Pharma Professional Research
    Mexico City, Mexico CITY (federal District) 03100, Mexico
  • OncoMed
    Mexico City, Mexico CITY (federal District) 03100, Mexico
  • Centro Médico Zambrano Hellion
    Monterrey, Nuevo León 66278, Mexico
  • Centro Medico Monte Carmelo
    Arequipa, 04001, Peru
  • Oncosalud Sac
    Lima, 41, Peru
  • Instituto Nacional de Enfermedades Neoplasicas
    Lima, Lima 34, Peru
  • Instituto Peruano de Oncología y Radioterapia
    Lima, Peru
  • ?wi?tokrzyskie Centrum Onkologii
    Kielce, 25-734, Poland
  • Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii
    Krakow, 31-501, Poland
  • Medical Oncology Centre of Rosebank
    Johannesburg, 2196, South Africa
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Gangnam Severance Hospital, Yonsei University Health System
    Seoul, 06273, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Hospital Quiron de Madrid
    Pozuelo de Alarcón, Madrid 28223, Spain
  • Hospital Universitario Virgen de La Arrixaca
    El Palmar, Murcia 30120, Spain
  • National Taiwan Uni Hospital
    Taipei, 100, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Oct 2026, 38 months.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 38 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2023
First posted
May 10, 2023
StartActual
Jul 18, 2023
Primary completionActual
Oct 15, 2026
CompletionActual
Oct 15, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 2, 2026
Sites
1 site removed
Show 1 removed
  • Centro de Investigacion Clinica de Oaxaca · Oaxaca City, Mexico
Nov 2, 2026
Primary completion
Oct 19, 2026→Oct 15, 2026 (actual)
Nov 2, 2026
Study completion
Oct 19, 2026→Oct 15, 2026 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Active, not recruiting→Completed
    1 site removed
    Show 1 removed
    • Centro de Investigacion Clinica de Oaxaca · Oaxaca City, Mexico
    Primary completion Oct 19, 2026→Oct 15, 2026 (now actual)
    Study completion Oct 19, 2026→Oct 15, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05852691
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 10, 2023
Start date
Jul 18, 2023
Primary completion
Oct 15, 2026
Completion
Oct 15, 2026
Last update
Nov 2, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tobemstomig

Start the discussion